C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR
Market Cap: 3.7B EUR

CTI Biopharma Corp
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

CTI Biopharma Corp
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
C
CTI Biopharma Corp
F:CEPS
EPS (Diluted)
$0
CAGR 3-Years
8%
CAGR 5-Years
2%
CAGR 10-Years
26%
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

CTI Biopharma Corp
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.

CEPS Intrinsic Value
Not Available

See Also

What is CTI Biopharma Corp's EPS (Diluted)?
EPS (Diluted)
-0.5 USD

Based on the financial report for Mar 31, 2023, CTI Biopharma Corp's EPS (Diluted) amounts to -0.5 USD.

What is CTI Biopharma Corp's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
26%

Over the last year, the EPS (Diluted) growth was 56%. The average annual EPS (Diluted) growth rates for CTI Biopharma Corp have been 8% over the past three years , 2% over the past five years , and 26% over the past ten years .

Back to Top